SPPL2 Antibody

Definition and Target

The SPPL2 antibody is a research tool designed to detect and study signal peptide peptidase-like 2A (SPPL2a), an aspartic intramembrane protease belonging to the peptidase A22B family. SPPL2a localizes to lysosomes/late endosomes and plays critical roles in immune regulation by cleaving substrates such as CD74, TNFα, and FasL. Antibodies targeting SPPL2a enable researchers to investigate its expression, function, and role in diseases like autoimmune disorders .

Biological Significance of SPPL2a

SPPL2a is essential for antigen-presenting cell (APC) development and function:

• B Cell Survival: Cleaves the CD74/p8 fragment, preventing its accumulation, which otherwise induces apoptosis in transitional B cells .

• Dendritic Cell Maturation: Regulates myeloid dendritic cell (mDC) populations by degrading CD74-NTF .

• Immune Modulation: Deficiency in SPPL2a disrupts MHC-II trafficking, impairing humoral immunity and antigen presentation .

SPPL2a inhibition (e.g., via small-molecule compounds like SPL-707) reduces mature B cells and mDCs, suggesting therapeutic potential for autoimmune diseases .

Table 2: Performance in Standard Assays

*MW discrepancies arise from glycosylation or dimerization .

Role in B Cell Development

• CD74 Processing: SPPL2a deficiency in mice causes CD74/p8 accumulation, leading to B cell apoptosis and reduced serum immunoglobulins .

• Therapeutic Potential: Inhibiting SPPL2a with compounds like SPL-707 recapitulates knockout phenotypes, suggesting utility in autoimmune therapy .

Substrate Specificity

SPPL2a cleaves type II transmembrane proteins, including:

• TNFα: Regulates inflammatory cytokine production .

• FasL: Modulates apoptotic signaling .

• CD74: Critical for MHC-II antigen presentation .

Disease Associations

• Autoimmunity: SPPL2a inhibition depletes pathogenic B cells, mimicking effects of anti-CD20 therapies (e.g., Rituximab) .

• Cancer: Cross-reactivity with γ-secretase (Notch pathway) raises safety concerns, necessitating selective inhibitors .

Validation and Challenges

• Selectivity: SPPL2 antibodies must distinguish SPPL2a from homologs (SPPL2b/c) and γ-secretase .

• Glycosylation Variability: Observed molecular weights range from 58–140 kDa due to post-translational modifications .

Future Directions

• Inducible Models: Required to assess SPPL2a inhibition in mature immune cells without developmental biases .

• Clinical Translation: SPPL2a inhibitors (e.g., SPL-707) warrant evaluation in autoimmune disease models .